synthesis of biologically active natural products, development of new synthetic methods, heterocyclic chemistry, DNA-agent interactions, antitumor antibiotics
Hey @Support@Safety@X,
Our lab account @BaranLabReads was suddenly suspended, but we have exciting science to share! Appeal was submitted can you please help?
Calling on our science collaborators & friends to please RT for visibility. @ScrippsResearch
Prof. Jin-Quan Yu (@YulabJin) will receive the 5th Akira Suzuki Award for his research on CβH bond activation, which makes it easier to build complex molecules. His work accelerates advances in pharmaceuticals, molecular tools and materials science.
More: https://t.co/MyD2K4HLgA
@KUPharmacy A giant among giants. Rigorous application of (physical) organic chemistry to drug metabolism, deep scholarship, fabulous mentor, and kindest of gentleman. Best of the best and crushing loss for us all
The amazing Lois and Bob (the reason I came to KU) Hanzlik starting an endowment at Peaslee Tech β a vocational school in Lawrence.
https://t.co/doESJmX84e
Insights into Free Drug Release from Efficacious N-Acyl O-Aminophenol Duocarmycin Prodrugs | ACS Chemical Biology https://t.co/URrACvEcrs
Provocative observations made in wonderful collaborations that reveal an exclusive protein-mediated prodrug activation in cancer cells
@KUPharmacy Fantastic lectureship honoring a great scientist (Smissman) who championed the role and importance of Organic Chemistry in Medicinal Chemistry. So glad Ben will be among the list of speakers in this prestigious series!
The Smissman Memorial Lecture series continues tomorrow featuring Scripps Research Institute's Benjamin Cravatt. A scientific lecture is at 9 am in PHAR 1020 and the main lecture is at 4 pm in the Big 12 Rm. of the Kansas Union. The public is invited.
@saveantibiotics@koutterson An initiative that would bring big pharma back into the area would be to grant any company that successfully introduces a new antibiotic into the clinic be granted a 5 year extension on ANY one drug product they have in their portfolio. Every company would be very motivated
@UKAMREnvoy@saveantibiotics@FlemingCentre@UKUN_NewYork@FCDOGovUK@UKgovGHS@Ara_Darzi Bring up the rumored, but great, proposal for truly incentivizing new antibiotic development: provide a company that introduces a new antibiotic into the clinic with an exclusive 5 yr extension to ANY product/patent in its portfolio (not just the antibiotic)